| Similar Articles |
|---|
 |
Pharmaceutical Executive
May 1, 2011
Julian Upton |
UK Stakeholders Have Their Say on Value-Based Pricing The UK coalition government's consultation on the intro of value-based pricing has invited caution and resistance.   |
Pharmaceutical Executive
May 1, 2012 |
Value-Based Pricing: Too High a Price for UK Pharma? Changes to the system in the UK could finally put some real metrics behind the elusive concept of value but with payers clearly in the driver's seat, who needs clarity? |
Pharmaceutical Executive
October 1, 2014
Leela Barham |
The Gate Keeper Dr. David Haslam, Chair of the UK's National Institute of Health and Care Excellence, discusses what the quantitative calculations of value mean to patient access in today's messy world of real-time medicine. |
Pharmaceutical Executive
April 1, 2007
Sarah Houlton |
Global Report: If It Ain't Broke Under the UK's pricing scheme, drug prices have dropped by 21% in 10 years. Is it really time for a change? |
Pharmaceutical Executive
August 1, 2008
Sarah Houlton |
Jumping the Gun The Association of the British Pharmaceutical Industry and the British government have come up with a solution for price regulation that isn't as bad as the industry had feared. |
Chemistry World
June 18, 2008
Ananyo Bhattacharya |
Deal on NHS drugs set to trim pharma profits An agreement between the UK government and the pharmaceutical industry will cut around five per cent off the cost of medicines sold to the National Health Service |
Pharmaceutical Executive
November 1, 2005
Sarah Houlton |
Global Report: Drug Evaluation in the UK The availability of new medicines has been thrown into the limelight once more, with UK's National Institute for Health and Clinical Excellence being called upon to make dramatic improvements to the speed at which it carries out evaluations. |
Pharmaceutical Executive
July 1, 2012
Ben Comer |
John Lechleiter on PhRMA and Innovation Eli Lilly CEO John Lechleiter on his agenda as incoming chairman of PhRMA, US healthcare reform, the euro crisis, and the small problem, of innovation. |
Pharmaceutical Executive
January 21, 2014
Comer & Upton |
Pharm Exec's Annual Industry Outlook 2014 For Big Pharma, the merits of strategic focus and operational discipline are more important than ever. It is time to be decisive; muddling through is so yesterday. |
Chemistry World
March 7, 2008
Peter Mitchell |
Uk Drug Pricing System Scrapped The UK government is scrapping its existing national scheme for controlling drug prices. The system, called the Pharmaceutical price regulation scheme (PPRS), will be replaced by a newly negotiated agreement on 1 September 2008. |
Chemistry World
April 2007
Richard Barker |
Comment: Pricing Pills An Office of Fair Trading report claims The UK's National Health Service is paying over the odds for its drugs, but this is not so. Medicine prices are 21% lower in real terms than ten years ago. |
Pharmaceutical Executive
December 1, 2011 |
UK Report: Keep Calm and Carry On ... Differently Even as the global economic roller coaster affects one of the country's dearest public institutions, the National Health Service, there is still reason for optimism in these times of austerity. |
Chemistry World
November 21, 2008
Pete Mitchell |
UK drug price deal finalised The new deal is guaranteed to continue for five years - a great relief to the industry. |
Pharmaceutical Executive
December 1, 2006
Sarah Houlton |
Global Report: Not So NICE A new manifesto by the Association of the British Pharmaceutical Industry is designed to improve drug access in the UK, where industry has worried for years about poor uptake of new medicines. |
Pharmaceutical Executive
May 1, 2006
Sarah Houlton |
Global Report: A Hope and a Payer If current trends continue, the United Kingdom will spend 12.7 percent of its GDP on healthcare by 2050. Maybe that means it's time to reform the National Health Service's notoriously complex drug payment scheme. |
Pharmaceutical Executive
July 3, 2007
Sarah Houlton |
Global Report: Five-Year Survivor: European Edition The UK government's attitude seems to be that oncology treatments are hugely expensive -- and that too much of the National Health Service budget is vanishing into the pockets of drug companies. Will cancer networks fill the gap? |
Pharmaceutical Executive
November 1, 2014
Jill Wechsler |
Outrage Grows Over Drug Pricing Insurers, physicians attack high-cost therapies in anticipation of specialty drug surge. |
Pharmaceutical Executive
October 1, 2008
Sarah Houlton |
Open For Debate Tensions mount as stakeholders in the UK health industry attempt to work out drug cost problems. |
Pharmaceutical Executive
February 1, 2007
Sarah Houlton |
Global Report: Under One Roof The UK government is planning to set up a single body to oversee all health research in universities and hospitals - and to facilitate partnerships between government agencies and industry. |
Chemistry World
July 2010 |
Meeting Mr NICE guy Bibiana Campos-Seijo meets the chief executive of the National Institute for Health and Clinical Excellence, Sir Andrew Dillon |
Chemistry World
March 17, 2014
Phillip Broadwith |
UK to fast-track access to critical medicines Critically ill patients in the UK could receive new medicines before they are formally approved under a new scheme beginning in April. |
Chemistry World
September 7, 2015 |
Cancer Drugs Fund axes 23 treatments The Cancer Drugs Fund, which covers the cost of some cancer treatments that are not currently available on the National Health Service, has cut 23 treatments -- involving 16 drugs. |
Pharmaceutical Executive
April 1, 2012
Feam & Lagus |
Providing Access Now While regulatory frameworks and medical practices differ between countries, many patients still need early access to new drugs. Industry can help. |
Pharmaceutical Executive
May 1, 2005
Sarah Houlton |
Global Report: Iron Fist The United Kingdom is hardening its stance on pharma industry issues. |
Chemistry World
December 8, 2011
Maria Burke |
Government Launches UK Life Sciences Strategy Prime minister David Cameron has announced a package of measures designed to boost the UK's life sciences industry. |
The Motley Fool
August 22, 2006
Brian Gorman |
NICE Unkind to Biotech Developments in the U.K.'s drug coverage may hurt U.S. biotechs. Biotech investors, keep your eyes on this issue. |
Chemistry World
March 20, 2008
Richard Van Noorden |
UK Drug Firms to Slash Research and Jobs The UK pharmaceutical industry is expecting to cut jobs and investment in R&D following an alarming slump in confidence in the UK market. |
Chemistry World
May 2006
Bea Perks |
Editorial: Generics in the Dock The manufacturers of generic medicines in the U.K. must work harder to guard their good reputation. Or perhaps, manufacturers of generic medicines must work harder to counter their bad reputation. |
Global Services
February 29, 2008
Imrana Khan |
A Mammoth Project Gone Awry NHS National Program for IT is an outsourcing project steeped in complexity, but thriving amidst a heap of controversies. Its veritably a study of sorts in large scale outsourcing of public sector transformation projects |
Chemistry World
May 25, 2011
Sarah Houlton |
Cost-cutting will stifle UK innovation The UK government's cost-cutting policies are in danger of stifling innovation, according to a report from The Work Foundation. |
